ICM
LAB icon

Invenomic Capital Management’s Standard BioTools LAB Stock Holding History

Invenomic Capital Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-950,114
Closed -$1.68M – 165
2024
Q2 		$1.68M Buy
+950,114
New +$2.32M 0.08% 149

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invenomic Capital Management's LAB Position: Q3 2024 in Review

Invenomic Capital Management sold out of Standard BioTools (LAB) in Q3 2024, closing a stake of 950,114 shares — an estimated $1.68M sold.

Invenomic Capital Management first reported a position in LAB in Q2 2024 and held it in 1 quarter. The position peaked at $1.68M in Q2 2024. 141 funds tracked by Wall St. Rank hold LAB as of Q3 2024.

  • Invenomic Capital Management reported no remaining Standard BioTools position as of Q3 2024 after selling out during the quarter.
  • Invenomic Capital Management sold 950,114 Standard BioTools shares in Q3 2024, an estimated $1.68M.
  • Invenomic Capital Management first reported a position in Standard BioTools in Q2 2024 and held it in 1 quarter.
  • Invenomic Capital Management's Standard BioTools position peaked at $1.68M in Q2 2024.
  • 141 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2024.

Based on Invenomic Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.